The TRAILBLAZER-ALZ 2 (NCT04437511) study aimed to evaluate the efficacy and safety of Donanemab in early symptomatic AD patients, with participants stratified based on their levels of Tau protein, a predictive biomarker for AD progression. This evidence concerns the gene MAPT and Alzheimer disease.